A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy And Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Vibozilimod (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms SOLARES-PsO-1
- Sponsors Sun Pharmaceutical Industries
- 22 Oct 2024 Planned End Date changed from 1 Nov 2024 to 1 Apr 2025.
- 22 Oct 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Nov 2024.
- 22 Oct 2024 Status changed from recruiting to active, no longer recruiting.